March 3, 2026Open Access

Real-world evidence of clinical outcomes and adherence to ofatumumab in the UK and the impact of a patients support programme: A retrospective, non-interventional cohort study

Key Points

Clinical effectiveness is supported by reduced annualized relapse rate (ARR) post-ofatumumab initiation, showing promising results for RMS patients.
A strong patient support program complements ofatumumab adherence, enhancing RMS management in real-world settings.
Retrospective, non-interventional cohort analysis across the UK provides comprehensive evidence for ofatumumab's role in clinical use.
The findings endorse long-term use of ofatumumab, highlighting its safety profile and overall tolerability for RMS patients.

Abstract

This study provides evidence of good adherence for RMS patients using ofatumumab. Further, there is evidence of clinical effectiveness based on reduction in ARR post-ofatumumab initiation, as well as tolerability and a favourable safety profile. The results of this study support the continued use of ofatumumab in providing effective RMS disease management in the UK NHS.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Paling et al. (Tue,) studied this question.

synapsesocial.com/papers/69a75a87c6e9836116a20776 https://doi.org/https://doi.org/10.1016/j.msard.2026.107030

Bookmark

View Full Paper